 Home > Medical News > Latest Medical News > Junjing Bio's Aurora A Inhibitor Approved for Clinical Treatment of Advanced Cancer in China

Junjing Bio's Aurora A Inhibitor Approved for Clinical Treatment of Advanced Cancer in China

 Last Update: 2022-03-09
 Source: Internet
 Author: User

Tags

norco drug

intermezzo drug

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

TextPharmaceutical Guanlan

The official website of the Center for Drug Evaluation (CDE) of the State Food and Drug Administration of China recently announced that the Class 1 new drug WJ05129 tablets declared by Junjing Bio has obtained the implied license for clinical trials and is intended to be used for advanced cancers for which there is currently no effective treatment

Screenshot source: CDE official website

According to public data, Aurora kinase is a serine/threonine protease that regulates cell mitosis

Studies have shown that the combination of Aurora A inhibitor and KARS G12C inhibitor can overcome the latter's resistance, and has a synthetic lethal effect with RB1 gene deletion or inactivation, and can be used for the treatment of small cell lung cancer and triple-negative breast cancer.

According to public information, in addition to JS112, Junjing Bio has a number of drugs that have been approved for clinical trials in China

The other is the XPO1 inhibitor WJ01024 tablets (project code JS110), which is a small molecule inhibitor of the nuclear export protein XPO1, which can inhibit the nuclear export of various tumor suppressor proteins including p53 and enhance the function of tumor suppressor proteins

According to the cooperation agreement reached between Junshi Bio and Weijing Bio in 2020, Junshi Bio will obtain 50% of the rights and interests of the four drugs under development of Weijing Bio, as well as the exclusive production rights and entrusted production worldwide after approval.

This time, the Aurora A inhibitor JS112 has been approved for clinical use, which means that the cooperation between Junshi Bio and Microenvironment has ushered in new progress

References:

[1] China National Medical Products Administration Center for Drug Evaluation (CDE).

[3] Junshi Biotech voluntarily disclosed the announcement on the approval of Aurora A inhibitor JS112 for clinical trials.

[4] Official website of drug clinical trial registration and information publicity platform

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.